Business ❯ Pharmaceuticals ❯ Biotechnology
Acquisitions Clinical Research Clinical Trials Obesity Treatments Molecular Glue Degraders Weight Loss Drugs Cancer Treatment Prostate Cancer Therapeutics Myelofibrosis Collaboration Cystic Fibrosis Treatments Autoimmune Diseases FDA Regulations Collaborations Licensing Agreements Evotec SE RNAi Therapeutics Collaboration Agreements Market Potential Bispecific Antibodies Blood Coagulation Treatments RNA Technology Antibody Therapy Immunology Rare Diseases Monte Rosa Therapeutics Market Access Efzofitimod Artificial Intelligence Generative AI Monoclonal Antibodies Regulatory Affairs Sales Performance CNS Treatments CAR T-cell Therapy Oral Biologics
Want to see what podcasts are saying about this topic? Search across 130K+ podcasts. Explore Radar
The cash deal brings an investigational treatment‑resistant depression drug into Lilly’s lineup and signals a deliberate move to diversify beyond its GLP‑1 weight‑loss franchise.
